Lupin Limited has announced that its Board of Directors will convene on May 7, 2026, to review and approve the company's financial performance for the fourth quarter and full year ended March 31, 2026. The pharmaceutical company communicated this development to both the National Stock Exchange of India Limited and BSE Limited on April 22, 2026.

Board Meeting Agenda

The primary objectives of the scheduled board meeting include comprehensive review of the company's financial performance and strategic decisions for stakeholder returns.

Trading Window Restrictions

In accordance with regulatory compliance requirements, Lupin has implemented trading restrictions for designated personnel. The company has established a trading window closure period to ensure adherence to insider trading regulations.

Regulatory Compliance

The board meeting intimation follows Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window closure aligns with the company's Code of Conduct for Prohibition of Insider Trading and SEBI's Prohibition of Insider Trading Regulations, 2015.

The communication was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer, emphasizing the company's commitment to transparent corporate governance and regulatory adherence. Stakeholders and investors will receive the financial results and any dividend announcements following the board meeting conclusion.

Lupin Limited has officially launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States following approval from the U.S. FDA. The pharmaceutical company announced this significant milestone, marking another important addition to its diabetes treatment portfolio in the American market.

FDA Approval and Product Specifications

The launch follows the approval of Lupin's Abbreviated New Drug Application (ANDA) from the U.S. FDA, which confirmed the product as bioequivalent to Xigduo XR for approved labeling indications. The company has introduced the combination therapy in multiple dosage strengths to meet diverse patient needs.

Market Expansion Strategy

This product launch reinforces Lupin's commitment to expanding its presence in the US pharmaceutical market. The introduction of FDA-approved diabetes treatment medications aligns with the company's strategy to strengthen its portfolio in key therapeutic areas where there is significant patient demand.

Therapeutic Significance

The combination of Dapagliflozin and Metformin Hydrochloride in an extended-release formulation offers healthcare providers and patients an additional treatment option in diabetes management. Extended-release formulations typically provide improved patient compliance through reduced dosing frequency compared to immediate-release alternatives.

Company Profile

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets worldwide. The company maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a dedicated workforce of over 24,000 professionals across multiple therapy areas including anti-diabetic treatments.